Biocon's subsidiary, Biocon Biologics, has introduced Nepexto, a biosimilar to Enbrel (Etanercept), in Australia for treating ...

Biocon Biologics launches Nepexto, a biosimilar for autoimmune diseases like rheumatoid arthritis, in Australia. The drug ...

Biocon Biologics, a subsidiary of Biocon, has introduced Nepexto, a biosimilar to Enbrel, in the Australian market for ...

Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced it ...

Biocon advanced 1.34% to Rs 392.25 after the company said that Biocon Biologics (BBL) has launched Nepexto, a biosimilar to the reference product Enbrel (Etanercept), in Australia.

Etanercept is a TNF (tumor necrosis factor) inhibitor used to treat several autoimmune conditions, including rheumatoid ...

Biocon Biologics (BBL), a fully integrated global biosimilars company and subsidiary of Biocon, announced today it has launched Nepexto, a biosimilar to the reference product Enbrel (Etanercept), in ...

The shares of biopharmaceutical firm Biocon fell as much as 2.04 per cent in Tuesday's trading session, figuring among top ...

Shares of Biocon experienced a decline of 2.01% to Rs 386.70 in Tuesday's session, with the stock figuring among the top ...

With the stock currently trading at Rs 405.05, Biocon has demonstrated strong financial performance and positive investor sentiment, as reflected by its 52-week high and bullish market outlook.

The U.S. FDA on July 15 cleared Biocon Biologics Ltd.’s Kirsty (insulin aspart-xjhz) as the first and only interchangeable ...

Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...